Age-related changes of blood pressure and heart rate in patients with Parkinson’s disease: Is there any effect of antiparkinsonian drugs?
This 16-year longitudinal study of 32 Parkinson's disease patients reveals that systolic blood pressure gradually declines with disease duration over more than a decade, while heart rate remains stable, with neither trend significantly associated with the use of antiparkinsonian medications or increases in levodopa-equivalent daily doses.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For people living with Parkinson's disease, the body's internal control systems often begin to falter long before the tremors or stiffness become obvious. One of the most critical systems to struggle is the autonomic nervous system, the invisible network that manages automatic functions like digestion, sweating, and, crucially, blood pressure. In a healthy body, this system acts like a vigilant regulator, ensuring that blood pressure stays steady whether a person is sitting, standing, or moving. However, in Parkinson's, this regulation frequently breaks down, leading to a condition called orthostatic hypotension, where blood pressure drops too low when standing up. This can cause dizziness, fainting, and a dangerous reduction in blood flow to the brain. While doctors have long known that these blood pressure issues become more common as the disease progresses, a lingering question remained: is this decline simply a natural part of getting older with the disease, or is it caused by the very medications used to treat the tremors and stiffness?
To answer this, a team of researchers at the University of Yamanashi in Japan decided to look at the long-term history of blood pressure in individual patients. They gathered medical records from thirty-two people with Parkinson's disease who had been visiting their clinic regularly for sixteen years. These patients were carefully selected to ensure they had the classic form of the disease and were not taking other medicines that could confuse the results, such as drugs for high blood pressure or depression. The researchers focused on three specific measurements taken every two months: the pressure in the arteries when the heart beats, the pressure when the heart rests between beats, and the speed of the heartbeat. They wanted to see if these numbers drifted over time and, if they did, whether the drift was linked to the amount of Parkinson's medication the patients were taking. The medication dosage was tracked using a standard calculation that converts different types of Parkinson's drugs into a single equivalent amount of levodopa, the most common treatment for the condition.
The results of this sixteen-year observation revealed a clear and steady pattern. As the patients lived longer with Parkinson's disease, their systolic blood pressure—the top number that measures the force of blood against artery walls during a heartbeat—slowly but significantly decreased. On average, this pressure dropped by about 0.67 millimeters of mercury every single year. By the time the patients reached the eleventh year of their observation, their average blood pressure was noticeably lower than it had been at the start. The pressure in the arteries when the heart rested also showed a slight downward trend, though this change was not as statistically strong. The speed of the heartbeat, however, remained remarkably stable, showing no significant change over the decade and a half.
Crucially, the study found that this slow decline in blood pressure was not driven by the medications. The researchers compared two groups of patients: those taking only levodopa and those taking a combination of levodopa and other drugs called dopamine agonists. Both groups experienced the same gradual drop in blood pressure over time. Furthermore, when the researchers looked at whether increasing the total daily dose of medication correlated with a faster drop in blood pressure, they found no connection at all. Whether a patient's medication dose went up or stayed the same, their blood pressure followed the same gentle downward slope. This finding challenges the common assumption that the long-term use of Parkinson's drugs is the primary culprit behind the worsening blood pressure issues seen in these patients.
The study concludes that the drop in blood pressure is likely an intrinsic part of the disease's progression over time, rather than a side effect of the treatment. This distinction is vital for doctors and patients alike. It suggests that managing blood pressure in Parkinson's requires looking beyond the medication list and focusing on the natural evolution of the disease itself. By understanding that this decline is a slow, steady process that happens regardless of drug dosage, clinicians can better anticipate these changes and manage them to prevent dizziness or fainting, ensuring that the brain continues to receive the steady flow of blood it needs to function properly.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.